460,853 Shares in Moderna, Inc. $MRNA Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 460,853 shares of the company’s stock, valued at approximately $13,591,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Federation des caisses Desjardins du Quebec increased its holdings in shares of Moderna by 3.1% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 44,936 shares of the company’s stock valued at $1,325,000 after purchasing an additional 1,346 shares during the period. Brooklyn Investment Group purchased a new stake in shares of Moderna during the fourth quarter worth approximately $571,000. Elevated Private Wealth LLC acquired a new stake in shares of Moderna during the fourth quarter worth $1,046,000. Cibc World Markets Corp acquired a new stake in shares of Moderna during the fourth quarter worth $1,071,000. Finally, Kintegral Advisory LLC purchased a new position in Moderna in the 4th quarter valued at $85,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Performance

NASDAQ:MRNA opened at $49.91 on Friday. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $59.55. The stock has a market cap of $19.80 billion, a PE ratio of -6.12 and a beta of 1.05. The firm’s fifty day simple moving average is $49.61 and its 200-day simple moving average is $44.03.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The company had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm’s revenue for the quarter was up 260.2% on a year-over-year basis. During the same quarter last year, the business earned ($2.52) EPS. Analysts expect that Moderna, Inc. will post -6.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Royal Bank Of Canada boosted their price objective on shares of Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a research note on Monday, May 4th. Sanford C. Bernstein restated a “market perform” rating and issued a $45.00 target price on shares of Moderna in a research note on Tuesday, February 17th. Piper Sandler boosted their price target on shares of Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research note on Monday, February 23rd. Bank of America increased their price target on shares of Moderna from $32.00 to $34.00 and gave the stock an “underperform” rating in a report on Monday, June 8th. Finally, The Goldman Sachs Group raised their price objective on shares of Moderna from $43.00 to $49.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $36.60.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 9,263 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the sale, the director owned 3,924 shares in the company, valued at $183,800.16. This represents a 70.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $48.40, for a total value of $2,581,462.40. Following the completion of the transaction, the president directly owned 1,477,997 shares of the company’s stock, valued at $71,535,054.80. The trade was a 3.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 71,752 shares of company stock valued at $3,453,843. 10.80% of the stock is currently owned by corporate insiders.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.